AKR1C3 and prostate cancer: Overall, these results suggest that ERRα could function to promote the intratumoral DHT biosynthesis in prostate cancer or CRPC via its direct regulation of AKR1C3 expression and also pharmacological suppression of ERRα activity could reduce the DHT production in prostate cancer cells.